ヘパリンの世界市場：洞察、競合情勢、市場予測：2032年

ヘパリンの市場規模は、2024年には97億6,761万米ドルとなりました。同市場は、2025年から2032年までの予測期間中に8.12%のCAGRで拡大し、2032年には181億8,809万米ドルに達すると予測されています。世界のヘパリン市場は、医薬品市場を形成する様々な要因によって推進されています。まず、心血管障害とがんの世界の有病率の上昇がヘパリン需要を牽引しています。これらの疾患は、生命を脅かす血栓を予防するために抗凝固療法を必要とすることが多いからです。加えて、特に手術、外傷、腫瘍治療における全血および血液成分の輸血需要の増大が、輸血処置中の血栓形成を防止する上で極めて重要なヘパリンの必要性をさらに後押ししています。さらに、低分子量ヘパリン（LMWH）や新規製剤の進歩を含む世界の製品開発活動の高まりは、ヘパリンの入手しやすさと安全性を高め、2025年から2032年までの予測期間中の市場全体の成長を後押ししています。

世界心臓連盟（2024年）によると、世界で約6,000万人が心房細動に罹患しています。また、同資料によると、心房細動患者は脳卒中になる可能性が5倍高くなっています。

さらに、英国心臓財団（British Heart Foundation）が提供した最近のデータ（2024年）によると、全世界で、約5,600万人の女性と4,500万人の男性が脳卒中生存者でした。世界中で少なくとも1,300万人が先天性心疾患を抱えていると推定され、潜在的にはさらに数100万人が診断されていない可能性があります。

さらに、英国心臓財団が提供した最近のデータ（2024年）によると、冠動脈（虚血性）心疾患は、世界中で推定2億人が罹患しています。約1億1,000万人の男性と8,000万人の女性が罹患しています。さらに、約5,600万人の女性と4,500万人の男性が脳卒中の生存者でした。

不安定冠動脈疾患（CAD）の治療において、治療用量の未分画ヘパリンは死亡や心筋梗塞を含む虚血の有害な転帰を減少させるのに有効であることが証明されています。さらに，ヘパリンの静脈内投与は不安定冠動脈疾患発症後の将来の心イベントを予防する上で重要な役割を果たしています。同様の抗血栓特性を有する低分子ヘパリン（LMWH）は皮下投与の利点を有し，心血管系患者の長期管理に適しています。この柔軟性と有効性が相まって、心血管治療の重要な要素としてヘパリンに対する世界の需要が高まっています。

同様に、がん患者はしばしば血栓塞栓性合併症の開発リスクが高く、治療のために抗凝固薬の使用が必要となります。例えば、GLOBOCANが提供した最近のデータ（2024年）によれば、2022年に世界で新たに発生したがん患者数は2,000万人と推定され、2045年までに3,260万人増加すると予測されています。がん治療中の化学療法と長期の固定化は、がん関連血栓症が一般的な副作用であることから、この必要性をさらに高めています。抗凝固剤であるヘパリンは、血栓形成に関与するタンパク質を阻害することにより、血栓の予防と治療に役立ちます。これにより、深部静脈血栓症（DVT）、肺塞栓症、脳卒中といった疾患のリスクが軽減されるため、ヘパリンの需要は世界中で拡大しています。

さらに、ヘパリン市場は急速な成長を遂げており、製品開発、研究開発努力、臨床試験、および世界各地の規制当局の承認における著しい進歩が燃料となっています。例えば、2022年1月、OptimviaとGinkgo Bioworksは、現在工業的畜産から生産されている必須医薬品である生合成ヘパリンの製造効率を改善するための提携を発表しました。この提携により、オプティムビアはイチョウの細胞・酵素工学プラットフォームと発酵プロセス開発の専門知識を活用し、オプティムビアの生合成ヘパリン製造技術の性能を迅速に向上させることを目指します。

このように、上記の要因は、2025年から2032年までの予測期間中、全世界のヘパリン市場全体を押し上げると予想されます。

当レポートでは、世界のヘパリン市場について調査し、市場の概要とともに、由来別、投与経路別、用途別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 ヘパリン市場レポートのイントロダクション

第2章 ヘパリン市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 ヘパリン市場の主な要因分析

• ヘパリン市場の促進要因
• ヘパリン市場の抑制要因と課題
• ヘパリン市場の機会

第6章 ヘパリン市場におけるポーターのファイブフォース分析

第7章 ヘパリン市場の評価

• 由来別
  • 牛
  • 豚肉
  • その他
• 投与経路別
  • 皮下
  • 静脈内
• 用途別
  • 冠動脈疾患
  • 心房細動
  • 静脈血栓塞栓症
  • 腎機能障害
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 ヘパリン市場の企業と製品プロファイル

• Pfizer Inc.
• Dr. Reddy's Laboratories Ltd.
• Gland Pharma Limited
• Sanofi
• B. Braun Melsungen AG
• Fresenius SE & Co. KGaA
• Novartis AG
• Baxter
• Leo Pharma A/S
• Cardinal Health

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Heparin Market in Global (2022-2032)
• Table 3: Heparin Market in Global by Source (2022-2032)
• Table 4: Heparin Market in Global by Route of Administration (2022-2032)
• Table 5: Heparin Market in Global by Application (2022-2032)
• Table 6: Heparin Market in Global by Geography (2022-2032)
• Table 7: Heparin Market in North America (2022-2032)
• Table 8: Heparin Market in the United States (2022-2032)
• Table 9: Heparin Market in Canada (2022-2032)
• Table 10: Heparin Market in Mexico (2022-2032)
• Table 11: Heparin Market in Europe (2022-2032)
• Table 12: Heparin Market in France (2022-2032)
• Table 13: Heparin Market in Germany (2022-2032)
• Table 14: Heparin Market in the United Kingdom (2022-2032)
• Table 15: Heparin Market in Italy (2022-2032)
• Table 16: Heparin Market in Spain (2022-2032)
• Table 17: Heparin Market in the Rest of Europe (2022-2032)
• Table 18: Heparin Market in Asia-Pacific (2022-2032)
• Table 19: Heparin Market in China (2022-2032)
• Table 20: Heparin Market in Japan (2022-2032)
• Table 21: Heparin Market in India (2022-2032)
• Table 22: Heparin Market in Australia (2022-2032)
• Table 23: Heparin Market in South Korea (2022-2032)
• Table 24: Heparin Market in Rest of Asia-Pacific (2022-2032)
• Table 25: Heparin Market in the Rest of the World (2022-2032)
• Table 26: Heparin Market in the Middle East (2022-2032)
• Table 27: Heparin Market in Africa (2022-2032)
• Table 28: Heparin Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Heparin Market in Global (2022-2032)
• Figure 3: Heparin Market in Global by Source (2022-2032)
• Figure 4: Heparin Market in Global by Route of Administration (2022-2032)
• Figure 5: Heparin Market in Global by Application (2022-2032)
• Figure 6: Heparin Market in Global by Geography (2022-2032)
• Figure 7: Heparin Market in North America (2022-2032)
• Figure 8: Heparin Market in the United States (2022-2032)
• Figure 9: Heparin Market in Canada (2022-2032)
• Figure 10: Heparin Market in Mexico (2022-2032)
• Figure 11: Heparin Market in Europe (2022-2032)
• Figure 12: Heparin Market in France (2022-2032)
• Figure 13: Heparin Market in Germany (2022-2032)
• Figure 14: Heparin Market in the United Kingdom (2022-2032)
• Figure 15: Heparin Market in Italy (2022-2032)
• Figure 16: Heparin Market in Spain (2022-2032)
• Figure 17: Heparin Market in the Rest of Europe (2022-2032)
• Figure 18: Heparin Market in Asia-Pacific (2022-2032)
• Figure 19: Heparin Market in China (2022-2032)
• Figure 20: Heparin Market in Japan (2022-2032)
• Figure 21: Heparin Market in India (2022-2032)
• Figure 22: Heparin Market in Australia (2022-2032)
• Figure 23: Heparin Market in South Korea (2022-2032)
• Figure 24: Heparin Market in Rest of Asia-Pacific (2022-2032)
• Figure 25: Heparin Market in the Rest of the World (2022-2032)
• Figure 26: Heparin Market in the Middle East (2022-2032)
• Figure 27: Heparin Market in Africa (2022-2032)
• Figure 28: Heparin Market in South America (2022-2032)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Market Opportunities
• Figure 32: PORTER'S Five Force Analysis

Heparin Market by Source (Bovine, Porcine, and Others), Route of Administration (Subcutaneous and Intravenous), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of cardiovascular disorders and cancer globally, growing demand for whole blood and blood component transfusion and blood donation, and increase in product development activities across the globe.

The heparin market was valued at USD 9,767.61 million in 2024, growing at a CAGR of 8.12% during the forecast period from 2025 to 2032 to reach USD 18,188.09 million by 2032. The global heparin market is propelled by a convergence of factors shaping the pharmaceutical landscape. Firstly, the increasing prevalence of cardiovascular disorders and cancer globally is driving the demand for heparin, as these conditions often require anticoagulation therapy to prevent life-threatening blood clots. Additionally, the growing demand for whole blood and blood component transfusions, especially in surgeries, trauma cases, and oncology treatments, further supports the need for heparin, which is crucial in preventing clot formation during transfusion procedures. Furthermore, the rise in product development activities across the globe, including advancements in low molecular weight heparin (LMWH) and novel formulations, enhances the accessibility and safety of heparin, boosting its overall market growth during the forecasted period from 2025 to 2032.

Heparin Market Dynamics:

According to the World Heart Federation (2024), approximately 60 million population globally were affected by atrial fibrillation. Additionally, as per the same source people with atrial fibrillation are 5X times more likely to suffer a stroke.

Moreover, according to the recent data provided by the British Heart Foundation (2024), globally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.

Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, affected an estimated 200 million people globally. Approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors.

In the treatment of unstable coronary artery disease (CAD), therapeutic-dose unfractionated heparin has proven effective in reducing adverse ischemic outcomes, including death and myocardial infarction. Additionally, intravenous heparin plays a crucial role in preventing future cardiac events following an episode of unstable CAD. Low-molecular-weight heparin (LMWH), which shares similar antithrombotic properties, offers the advantage of subcutaneous administration and is well-suited for long-term management of cardiovascular patients. This flexibility, combined with its efficacy, has led to a rising global demand for heparin as a vital component of cardiovascular care.

Similarly, cancer patients are often at high risk of developing thromboembolic complications, which necessitates the use of anticoagulants for treatment. For instance, as per the recent data provided by GLOBOCAN (2024), in 2022, globally, the estimated number of new cases of cancer was 20 million and the projections were estimated to increase by 32.6 million by 2045. Chemotherapy and prolonged immobilization during cancer therapy further contribute to this need, as cancer-associated thrombosis is a common side effect. Heparin, an anticoagulant, helps prevent and treat these clots by inhibiting proteins involved in clot formation. This reduces the risk of conditions such as deep vein thrombosis (DVT), pulmonary embolism, and strokes, thus driving the growing demand for heparin in the market across the globe.

Additionally, the growing demand for whole blood and blood component transfusions and donations is significantly boosting the global heparin market, as heparin is essential in preventing clot formation during these processes. This anticoagulant ensures the safe handling of blood products, maintaining fluidity during collection, processing, and transfusion. According to the recent data provided by the World Health Organization (2023), globally, 118.5 million blood donations were collected in 2023, with 40% originating from high-income countries (WHO). The rate of blood donations per 1,000 people varies significantly by income level, further illustrating global disparities in access to blood and blood products. Heparin is vital in the collection and processing of these components, ensuring proper separation of RBCs, plasma, and platelets. As healthcare systems worldwide emphasize safe transfusion practices, the use of heparin in blood management protocols is increasing, driving the demand for heparin products and contributing to the overall growth of the global heparin market.

Furthermore, the heparin market is experiencing rapid growth, fueled by significant advancements in product development, R&D efforts, clinical trials, and regulatory approvals across the globe. For instance, in January 2022, Optimvia and Ginkgo Bioworks announced a partnership to improve the manufacturing efficiency of biosynthetic heparin, an essential medicine currently produced from industrial animal agriculture. Under the partnership, Optimvia seeks to leverage Ginkgo's cell and enzyme engineering platform, as well as its fermentation process development expertise, to rapidly improve the performance of Optimvia's biosynthetic heparin manufacturing technology.

Thus, the factors mentioned above are expected to boost the overall market of heparin across the globe during the forecast period from 2025 to 2032.

However, Potential and fatal side effects associated with the use of heparin and the availability of alternative methods of anticoagulation may hinder the future market of heparin across the globe during the forecasted period.

Heparin Market Segment Analysis:

Heparin Market by Source (Bovine, Porcine, and Others), Route of Administration (Subcutaneous and Intravenous), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The porcine category in the heparin market is estimated to dominate the market with a market share of 87.30% in 2024. Porcine-derived heparin is a major contributor to the growth of the heparin market due to its widespread use in medical treatments and the increasing demand for anticoagulant therapies globally. Heparin, which is primarily extracted from the intestines of pigs, plays a vital role in preventing and treating conditions like deep vein thrombosis, and pulmonary embolism, and in patients undergoing surgeries such as cardiac bypass, dialysis, and organ transplants. The global reliance on porcine-derived heparin stems from its efficacy, established safety profile, and long history of use in both hospital settings and outpatient care. As the number of surgeries and medical procedures requiring anticoagulation therapy rises, particularly with the aging population and increasing prevalence of cardiovascular diseases, the demand for heparin, including porcine-sourced versions, continues to grow.

Additionally, clinicians had substantial experience with porcine heparin, resulting in well-established dosing procedures and monitoring techniques. However, the reliance on a single animal source and country of origin emphasizes the need to diversify the heparin supply chain. Although both bovine and porcine heparin are efficient anticoagulants, their potency varies. Bovine heparin is only proven to be around two-thirds as powerful as swine heparin, which may demand dosage modifications when switching between the two sources, making porcine heparin a preferred choice in terms of potency.

Also, in October 2023, Miratorg, a Russian pork company and a Russian subsidiary of the Van Hessen Group opened the Geparinus factory in the Kursk region. The factory aimed to produce medicinal heparin in its basic form as well as hydrolyzed feed protein. Miratorg stated that Geparinus will process mucosa from both the company's slaughterhouses and other market competitors, and was designed to treat 40,000 tons of mucosa per year, producing 70 tonnes of medicinal heparin.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of heparin across the globe.

North America is expected to dominate the overall heparin market:

Among all regions, North America is estimated to hold the largest share of 38.59% in the global heparin market in 2024, growing at a CAGR of 7.62% during the forecast period from 2025 to 2032. This can be attributed to the increasing prevalence of chronic disorders such as cardiovascular diseases, and diabetes, among others. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of heparin across the region. Furthermore, the growing demand for whole blood and blood component transfusions and the increase in cancer cases can further propel the market across the region.

According to the recent data provided by the Centre for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults have been diagnosed with coronary heart disease.

Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (2024), approximately 12.1 million population in the United States will have atrial fibrillation by 2023.

Additionally, as per the same source each year, over 795,000 individuals in the United States experience a stroke. Of these, approximately 610,000 are first-time or new strokes. Nearly 185,000 strokes, accounting for almost 1 in 4, occur in people who have already had a stroke.

Heparin is widely used as an anticoagulant to prevent and manage complications associated with CVDs, including deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS). For patients undergoing cardiac surgeries, including coronary artery bypass grafting (CABG) or percutaneous coronary interventions (PCI), heparin is often administered to prevent clot formation during and after the procedure. Heparin's ability to quickly and effectively prevent thrombosis makes it a preferred choice for such high-risk cardiovascular treatments. Additionally, as the incidence of atrial fibrillation (AF) rises a condition that increases the risk of stroke and is commonly linked to cardiovascular diseases there is an increased need for anticoagulation therapy to reduce stroke risk, further boosting the demand for heparin.

Moreover, the increasing use of heparin highlights the rapid adoption and increases product approval across the region, which is expected to drive market growth. For instance, in November 2023, the FDA approved a taurolidine plus heparin (DefenCath(R)) catheter lock solution to reduce catheter-related bloodstream infections in patients receiving maintenance hemodialysis via a central venous catheter (CVC).

Thus, the above-mentioned factors are expected to escalate the market of heparin in the region.

Heparin Market Key Players:

Some of the key market players operating in the heparin market include Pfizer Inc., Dr. Reddy's Laboratories Ltd., Gland Pharma Limited, Sanofi, B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Novartis AG, Baxter, Leo Pharma A/S, Cardinal Health, and others.

Recent Developmental Activities in the Heparin Market:

• In June 2024, InsightRX and Northern Arizona Healthcare (NAH) announced that they had made InsightRX's precision dosing software for heparin therapy available to the pharmacists at Flagstaff Medical Center. NAH anticipated that this move would reduce the time needed to therapeutically dose hospitalized patients with unfractionated heparin, which was expected to enhance patient outcomes by improving the management of blood clot treatment and prevention.
• In February 2024, B. Braun Medical Inc. announced the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of heparin premixed bags. The launch reaffirmed B. Braun's commitment to improving the security of supply by manufacturing pharmaceuticals in the United States from its Irvine, CA, facility.

Key Takeaways From the Heparin Market Report Study

• Market size analysis for current heparin size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the heparin market.
• Various opportunities available for the other competitors in the heparin market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current heparin market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for heparin market growth in the coming future?

Target Audience Who Can be Benefited From This Heparin Market Report Study

• Heparin product providers
• Research organizations and consulting companies
• Heparin-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Heparin
• Various end-users who want to know more about the heparin market and the latest technological developments in the heparin market.

Frequently Asked Questions for the Heparin Market:

1. What is heparin?

• Heparin is a polysaccharide used as an injectable anticoagulant to prevent blood clotting in medical treatments. It is effective in managing conditions such as venous thromboembolism and coronary artery disease by reducing the risk of blood clot formation.

2. What is the market for heparin?

• The heparin market was valued at USD 9,767.61 million in 2024, growing at a CAGR of 8.12% during the forecast period from 2025 to 2032 to reach USD 18,188.09 million by 2032.

3. What are the drivers for the global heparin market?

• The global heparin market is propelled by a convergence of factors shaping the pharmaceutical landscape. Firstly, the increasing prevalence of cardiovascular disorders and cancer globally is driving the demand for heparin, as these conditions often require anticoagulation therapy to prevent life-threatening blood clots. Additionally, the growing demand for whole blood and blood component transfusions, especially in surgeries, trauma cases, and oncology treatments, further supports the need for heparin, which is crucial in preventing clot formation during transfusion procedures. Furthermore, the rise in product development activities across the globe, including advancements in low molecular weight heparin (LMWH) and novel formulations, enhances the accessibility and safety of heparin, boosting its overall market growth during the forecasted period from 2025 to 2032.

4. Who are the key players operating in the global heparin market?

• Some of the key market players operating in the heparin are Pfizer Inc., Dr. Reddy's Laboratories Ltd., Gland Pharma Limited, Sanofi, B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Novartis AG, Baxter, Leo Pharma A/S, Cardinal Health, and others.

5. Which region has the highest share in the global heparin market?

• North America is anticipated to dominate the overall heparin market owing to the increasing prevalence of chronic disorders such as cardiovascular diseases, and diabetes, among others. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of heparin across the region. Furthermore, the growing demand for whole blood and blood component transfusions and the increase in cancer cases can further propel the market across the region.

Table of Contents

1. Heparin Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Heparin Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Heparin Market Key Factors Analysis

• 5.1. Heparin Market Drivers
  • 5.1.1. Increasing prevalence of cardiovascular disorders and cancer globally
  • 5.1.2. Growing demand for whole blood and blood component transfusion and blood donation
  • 5.1.3. Increase in product development activities across the globe
• 5.2. Heparin Market Restraints and Challenges
  • 5.2.1. Potential and fatal side effects associated with the use of heparin
  • 5.2.2. Availability of alternative methods of anticoagulation
• 5.3. Heparin Market Opportunities
  • 5.3.1. Growing technological advancement and R&D activities focused on developing safer and more effective heparin treatments.

6. Heparin Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Heparin Market Assessment

• 7.1. By Source
  • 7.1.1. Bovine
  • 7.1.2. Porcine
  • 7.1.3. Others
• 7.2. By Route of Administration
  • 7.2.1. Subcutaneous
  • 7.2.2. Intravenous
• 7.3. By Application
  • 7.3.1. Coronary Artery Disease
  • 7.3.2. Atrial Fibrillation
  • 7.3.3. Venous Thromboembolism
  • 7.3.4. Renal Impairment
  • 7.3.5. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Heparin Market Size in USD Million (2022-2032)
    • 7.4.1.2. Canada Heparin Market Size in USD Million (2022-2032)
    • 7.4.1.3. Mexico Heparin Market Size in USD Million (2022-2032)
  • 7.4.2. Europe
    • 7.4.2.1. France Heparin Market Size in USD Million (2022-2032)
    • 7.4.2.2. Germany Heparin Market Size in USD Million (2022-2032)
    • 7.4.2.3. United Kingdom Heparin Market Size in USD Million (2022-2032)
    • 7.4.2.4. Italy Heparin Market Size in USD Million (2022-2032)
    • 7.4.2.5. Spain Heparin Market Size in USD Million (2022-2032)
    • 7.4.2.6. Rest of Europe Heparin Market Size in USD Million (2022-2032)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Heparin Market Size in USD Million (2022-2032)
    • 7.4.3.2. Japan Heparin Market Size in USD Million (2022-2032)
    • 7.4.3.3. India Heparin Market Size in USD Million (2022-2032)
    • 7.4.3.4. Australia Heparin Market Size in USD Million (2022-2032)
    • 7.4.3.5. South Korea Heparin Market Size in USD Million (2022-2032)
    • 7.4.3.6. Rest of Asia-Pacific Heparin Market Size in USD Million (2022-2032)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Heparin Market Size in USD Million (2022-2032)
    • 7.4.4.2. Africa Heparin Market Size in USD Million (2022-2032)
    • 7.4.4.3. South America Heparin Market Size in USD Million (2022-2032)

8. Heparin Market Company and Product Profiles

• 8.1. Pfizer Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Dr. Reddy's Laboratories Ltd.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Gland Pharma Limited
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Sanofi
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. B. Braun Melsungen AG
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Fresenius SE & Co. KGaA
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Novartis AG
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Baxter
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Leo Pharma A/S
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Cardinal Health
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us